期刊文献+

HBx基因缺失型突变体HBx-d382与HBx-d431原核表达载体的构建和鉴定

Construction of Prokaryotic Expression Vector Carrying HBx-d382 and HBx-d431 Genes from Hepatocellular Carcinoma Tissue
原文传递
导出
摘要 目的为探讨HBx基因缺失型突变体HBx-d382和HBx-d431在临床上应用的价值,构建HBx基因缺失型突变体HBx-d382和HBx-d431原核表达载体。方法以pGM-T/HBx-d382和pGM-T/HBx-d431质粒为模板,PCR扩增含EcoRⅠ和XhoⅠ酶切位点的HBx基因片段。HBx基因PCR扩增产物与载体pET-28a(+)经双酶切、连接,形成重组DNA后转化到大肠杆菌BL21(DE3)中,经卡那霉素筛选、酶切鉴定和DNA序列测定,筛选出重组HBx基因缺失型突变体原核表达载体。结果成功构建了重组pET-28a(+)/HBx-d382和pET-28a(+)HBx-d431原核表达载体,重组前后HBx基因片段序列一致。结论pET-28a(+)/HBx-d382和pET-28a(+)/HBx-d431原核表达载体构建成功,为HBx基因缺失型突变体HBx-d382和HBx-d431蛋白的免疫原性和临床应用的研究奠定了基础。 Objective To construct the prokaryotic expression vector carrying HBx-d382 and HBx-d431 genes for exploring the relationship between HBx deletion mutant and hepatocellular carcinoma. Methods HBx-d382 and HBx-d431 genes with EcoR I and Xho I endoenzyme sites were obtained by using PCR. The genes were cloned into pGM-T and produced pGM-T/HBx-d382 and pGM-T/HBx-d431 plasmids. The plasmids were transferred to E. coli BL21 (DE3). Recombinant plasmid sequence were subsequently verified by EcoR Ⅰ and Xho Ⅰ endoenzyme digestion and auto-sequencing assay. Results We have constructed the prokaryotic expression vector of HBx-d382 and HBx- d431 carrying the integrated HBx-d382 or HBx-d431 gene fragment. Conclusion pET-28a (+)/HBx-d382 and pET- 28a(+)/HBx-d431 prokaryotic expression vectors can be used for the study of HBx-d382 and HBx-d431 proteins.
出处 《热带医学杂志》 CAS 2009年第7期732-734,744,共4页 Journal of Tropical Medicine
基金 广东省医学科研基金(No.A2008645) 深圳市科技计划项目(No.200802144)
关键词 乙型肝炎病毒X基因 缺失型突变体 原核表达载体 hepatitis B virus X gene deletion mutant prokaryotic expression vector
  • 相关文献

参考文献2

二级参考文献29

  • 1林静,朱明华,曲建慧,李芳梅,倪灿荣.乙型肝炎病毒X基因经p53依赖性与非依赖性途径对p21^(WAF1)表达的影响[J].癌症,2004,23(7):749-755. 被引量:9
  • 2刘晓红,朱明华,曹晓哲,郑建明,陈颖.HBx蛋白羧基端缺失对肝癌细胞生物学行为的影响[J].癌症,2005,24(10):1213-1219. 被引量:13
  • 3Ping'an ZHU,Deming TAN,Zhongtian PENG,Fei LIU,Lin SONG.Polymorphism Analyses of Hepatitis B Virus X Gene in Hepatocellular Carcinoma Patients from Southern China[J].Acta Biochimica et Biophysica Sinica,2007,39(4):265-272. 被引量:29
  • 4Birrer RB, Birrer D, Klavins JV. Hepatocellular carcinoma and hepatitis virus [J]. Ann Clin Lab Sci, 2003,33( 1 ):39-54.
  • 5Tu H, Bonura C, Giannini C, et al. Biological impact of natural COOH-terminal deletions of hepatitis B virus X protein in hepatocellular carcinoma tissues [J]. Cancer Res, 2001,61(21) :7803-7810.
  • 6Sirma H, Giannini C, Poussin K, et al. Hepatitis B virus X mutants, present in hepatocellular carcinoma tissue abrogate both the antiproliferative and transactivation effects of HBx [J].Oncogene, 1999,18(34) :4848-4859.
  • 7Iavarone M, Trabut JB, Delpuech O, et al. Characterisation of hepatitis B virus X protein mutants in tumour and non-tumour liver cells using laser capture microdissection [J]. J Hepatol,2003,39(2): 253-261.
  • 8Murakami S, Cheong JH, Kaneko S. Human hepatitis virus X gene encodes a regulatory domain that represses transactivation of X protein [J]. J Biol Chem, 1994,269(21): 15118-15123.
  • 9Elmore LW, Hancock AR, Chang SF, et al. Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis [J]. Proc Natl Acad Sci USA, 1997,94(26): 14707-14712.
  • 10Feitelson MA, Clayton MM. X antigen/antibody markers in hepadnavirus infections. Antibodies to the X gene product (s)[J]. Gastroenterology, 1990,99(2): 500-507.

共引文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部